ImpediMed Limited Announces Official Release of SOZO Version 4.0 Software
May 25, 2021 at 04:22 am IST
Share
ImpediMed Limited announced the release of the next generation Version 4.0 software for the SOZO® Digital Health Platform. As foreshadowed in the recent quarterly Appendix 4C announcement, Version 4.0 has gone live on May 25, 2021 with a series of significant enhancements around usability, new applications and security. Within the first few hours of launch, over 70 customers have already successfully upgraded their software to Version 4.0. Improvements in the software over time have led to a continuously increasing ASP (Average Selling Price) for software licenses and a negligible customer churn rate of just 1%. Over time, ImpediMed expects similar upside resulting from the release of Version 4.0 from new features such as body composition reference ranges and a new license for Segmental Analysis, enriching clinician data and providing in-depth actionable information about patient health. Usability: In line with previous versions of software releases, there are a tremendous series of advancements in the SOZO Version 4.0 software, with a major revamp of the User Interface being the centrepiece of this release. An intuitive redesign makes the software even more intuitive and easier to use. Clinicians can now access and review data with ease. In addition, the information is customisable so clinicians can see the data in the format that is most meaningful to them. New Applications and Features: Featured in Version 4.0 for the first time are body composition reference ranges and Segmental Analysis. Body composition reference ranges give the clinician meaningful comparator data to better assess a patient's health, which is expected to lead to an increase in the adoption of the Body Composition module from within the existing customer base. The Segmental Analysis application opens new segments of the breast cancer reconstructive and lymphatic and plastic surgery markets. Based on feedback from a customer advisory board, Version 4.0 incorporates Notes and Tags, enabling clinicians to tag and make patient notes supporting clinical decision making and assist clinicians in the timely retrieval of valuable information. Version 4.0 has also allowed for the alignment of iOS and Android software, allowing for a streamlining of support and development going forward. Security: Enhanced privacy and security features such as Multi Factor Authentication (MFA) and Single SignOn (SSO) continue the track record of striving for the most stringent security measures to protect patient data. Version 3.0 brought HIPAA and Business Associate compliance and more recently HiTrust certification. Now, SOZO Version 4.0 further enhances the levels of security at the source of sign on with multifactor authentication and single sign on capability.
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Companyâs SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.